Skip to main content

Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact

In a blockbuster agreement, Guangzhou’s Akeso out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion. Summit Therapeutics will pay $500 million upfront and up to $4.5 billion in milestones.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.